The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation

Journal of Endocrinology

Volumn 184, Issue 1, 2005, Pages 129-140

  Zhang, Haifan ^a   McElrath, Tim ^a   Tong, Wei ^a   Pollard, Jeffrey W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; PROTEIN P107; RETINOBLASTOMA PROTEIN; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DNA SYNTHESIS; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; MITOGENICITY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; UTERUS;

ANIMALS; CDC2-CDC28 KINASES; CELL CYCLE; CELLS, CULTURED; CYCLIN A; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED STRAINS; PHOSPHORYLATION; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UTERUS;

EID: 13444291094     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.05987     Document Type: Article

References (59)

1. Altan N, Chen Y, Schindler M & Simon S 1999 Tamoxifen inhibits acidification in cells independent of the estrogen receptor. PNAS 96 4432-4437.
2. Baum M 1997 Tamoxifen. Endocrine-Related Cancer 4 237-243.
3. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J & van Leeuwen FE 2000 Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial Cancer Risk following Tamoxifen. Lancet 356 881-887.
4. Bocchinfuso WP & Korach KS 1977 Mammary gland development and tumorigenesis in estrogen receptor knockout mice. Journal of Mammary Gland Biology and Neoplasia 2 323-334.
5. Carthew P, Edwards RE & Nolan BM 1999 Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. Toxicology and Applied Pharmacology 158 24-32.
6. Chen B & Pollard JW 2003 Cyclin D2 compensates for the loss of cyclin D1 in estrogen-induced mouse uterine epithelial cell proliferation. Molecular Endocrinology 17 1368-1381.
7. Clarke CL & Sutherland RL 1990 Progestin regulation of cellular proliferation. Endocrine Reviews 11 266-301.
8. Daniel CW, Silberstein GB & Strickland P 1987 Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Research 47 6052-6057.
9. Dhillon NK & Mudryj M 2002 Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21 4626-4634.
10. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA & Sutherland RL 2003 Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocrine-Related Cancer 10 179-186.
11. Dutertre M & Smith CL 2000 Molecular mechanisms of selective estrogen receptor modulator (SERM) action. Journal of Pharmacology and Experimental Therapeutics 295 431-437.
12. Ewen ME, Sluss HK, Sherr CJ, Matsushime K, Kato H & Livingston DM 1993 Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73 487-497.
13. Fagg B, Martin L, Rogers LA, Clark BF & Quarmby VE 1979 A simple method for preparing pure samples of uterine epithelial cells. Journal of Reproduction and Fertility 57 335-345.
14. Finn CA & Martin L 1970 The role of the oestrogen secreted before oestrus in the preparation of the uterus for implantation in the mouse. Journal of Endocrinology 47 431-438.
15. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA & Sicinski P 1999 Rescue of cyclin D1 deficiency by knockin cyclun E. Cell 97 767-777.
16. Geum D, Sun W, Paik SK, Lee CC & Kim K 1997 Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: differential induction mechanism of cyclin D1 and D3. Molecular Reproduction and Development 46 450-458.
17. Haslam SZ 1988 Local versus systemically mediated effects of estrogen on normal mammary epithelial cell deoxyribonucleic acid synthesis. Endocrinology 122 860-867.
18. Hung H & Pollak M 1995 Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. Progress in Growth Factor Research 6 495-501.
19. Hyde-Dunn J & Jones GE 1997 Visualization of cell replication using antibody to proliferating cell nuclear antigen. In Basic Cell Culture Protocols, pp 341-349, edn 2. Eds JW Pollard & JM Walker. Totowa, NJ: Humana Press.
20. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL & Makela S 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Research 56 3954-3960.
21. Ismail SM 1996 The effects of tamoxifen on the uterus. Current Opinions in Obstetrics and Gynecology 8 27-31.
22. Jordan VC & Morrow M 1999 Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrine Reviews 20 253-278.
23. Kaye AM, Sheratzky D & Lindner HR 1972 Kinetics of DNA synthesis in immature rat uterus: age dependence and estradiol stimulation. Biochimica et Biophysica Acta 261 475-486.
24. Klotz DM, Hewitt SC, Korach KS & Diaugustine RP 2000 Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha. Endocrinology 141 3430-3439.
25. Korach KS 1994 Insights from the study of animals lacking functional estrogen receptor. Science 266 1524-1527.
26. Lai MD, Lee LR, Cheng KS & Wing LY 2000 Expression of proliferating cell nuclear antigen in luminal epithelium during the growth and regression of rat uterus. Journal of Endocrinology 166 87-93.
27. Lee TH, Chuang LY & Hung WC 1999 Tamoxifen induces p21 WAF1 and p27 KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 18 4269-4274.
28. Lee TH, Chuang LY & Hung WC 2000 Induction of p21 WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells. Oncogene 19 3766-3773.
29. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI & Bartek J 1997 Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes and Development 11 1479-1492.
30. McDonnell D 1999 The molecular pharmacology of SERMs. Trends in Endocrinology and Metabolism 10 301-311.
31. Martin L & Middleton E 1978 Prolonged oestrogenic and mitogenic activity of tamoxifen in the ovariectomized mouse. Journal of Endocrinology 78 125-129.
32. Martin L, Finn CA & Trinder G 1973 Hypertrophy and hyperplasia in the mouse uterus after oestrogen treatment: an autoradiographic study. Journal of Endocrinology 56 133-144.
33. Martin L, Pollard JW & Fagg B 1976 Oestriol, oestradiol-17β and the proliferation and death of uterine cells. Journal of Endocrinology 69 103-115.
34. Matsushime H, Roussel MF, Ashmun RA & Sherr CJ 1991 Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65 701-713.
35. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ & Kato JY 1994 D-type cyclin-dependent kinase activity in mammalian cells. Molecular and Cellular Biology 14 2066-2076.
36. Mueller MD, Pritts EA, Zaloudek CJ, Dreher E & Taylor RN 2003 Regulation of vascular endothelial growth factor by tamoxifen in vitro and in vivo. Gynecologic and Obstetric Investigation 55 119-124.
37. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW & Sutherland RL 1993 Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology 13 3577-3587.
38. Musgrove EA, Lee CSL, Buckley MF & Sutherland RL 1994 Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. PNAS 91 8022-8026.
39. Ohtsubo M & Roberts JM 1993 Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259 1908-1912.
40. Pearce ST, Liu H & Jordan VC 2003 Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. Journal of Biological Chemistry 278 7630-7638.
41. Planas-Silva MD & Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology 17 4059-4069.
42. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW & Sutherland RL 1997 Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibition association. Journal of Biological Chemistry 272 10882-10894.
43. Roberts JM 1999 Evolving ideas about cyclins. Cell 98 129-132.
44. Rumpel E, Michna H & Kuhnel W 1995 PCNA immunoreactivity in the uterus of rats after treatment with the antiestrogen tamoxifen. Anatomischer Anzeiger 177 133-138.
45. Sartor BM, Sartor O & Flanders KC 1995 Analogous tamoxifen and estrogen effects on transforming growth factor-betas 1 and 2 in the rat uterus. Reproductive Toxicology 9 225-231.
46. Sherr CJ 1994 G1 phase progression: cycling on cue. Cell 79 551-555.
47. Sherr CJ 1996 Cancer cell cycles. Science 274 1672-1677.
48. Sherr CJ & Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 13 1501-1512.
49. Smith CL, Nawaz Z & O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 657-666.
50. Sutherland R, Mester J & Baulieu EE 1977 Tamoxifen is a potent 'pure' anti-oestrogen in chick oviduct. Nature 267 434-435.
51. Tong W & Pollard JW 1999 Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E, A-cdk2 kinase activation and cell proliferation in uterine epithelial cells in mice. Molecular and Cellular Biology 19 2252-2264.
52. Tong W & Pollard JW 2002 Female Sex Steroid Hormone Regulation of Cell Proliferation in the Endometrium, pp 94-109. Eds SR Glasser, JD Aplin, LC Giudice & S Tabibzadeh. London: Taylor & Francis.
53. Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa → luteal transition. Cell Growth and Differentiation 9 787-794.
54. Travis RC & Key TJ 2003 Oestrogen exposure and breast cancer risk. Breast Cancer Research 5 239-247.
55. Watts CK, Sweeney KJ, Warlters A, Musgrove EA & Sutherland RL 1994 Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Research and Treatment 31 95-105.
56. Webb P, Lopez GN, Ugt RM & Kushner P 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 9 443-456.
57. Wilcken NR, Prall OW, Musgrove EA & Sutherland RL 1997 Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clinical Cancer Research 3 849-854.
58. Willen R, Willen H & Lindahl B 2002 Similarity of uterine mucosa changes in patients treated by raloxifen and tamoxifen. Anticancer Research 22 1121-1125.
59. Zindy F, den Besten W, Chen B, Rehg JE, Latres E, Barbacid M, Pollard JW, Sherr CJ, Cohen PE & Roussel MF 2001 Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18(Ink4c) and p19(Ink4d). Molecular and Cellular Biology 21 3244-3255.